Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371159 | 1.00 | MAPT (0.55) | MAPTABCB1CACNA1GKMT2AMAPK1 | |
| SCHEMBL1380255 | 1.00 | MAPT (0.55) | MAPTABCB1CACNA1GKMT2AMAPK1 | |
| SCHEMBL5367033 | 0.90 | KDM4E (0.51) | MAPTABCB1CACNA1GKMT2AALDH1A1 | |
| SCHEMBL5367014 | 0.90 | KDM4E (0.51) | MAPTABCB1CACNA1GKMT2AALDH1A1 | |
| SCHEMBL5370452 | 0.90 | KDM4E (0.51) | MAPTABCB1CACNA1GKMT2AALDH1A1 | |
| SCHEMBL1379950 | 0.89 | MAPT (0.54) | MAPTKMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL1379956 | 0.89 | MAPT (0.54) | MAPTKMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL5359251 | 0.89 | MAPT (0.54) | MAPTKMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL5370501 | 0.88 | PKM (0.56) | ABCB1KMT2AMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL5370489 | 0.88 | PKM (0.56) | ABCB1KMT2AMAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4806149-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | claimed |
| EP-1216244-A1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | Aventis Pharmaceuticals Inc. (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001019821-A1 | BENZISOXAZOLYL-, PYRIDOISOXAZOLYL- AND BENZTHIENYL-PHENOXY DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | MAPT 347/4885ABCB1 388/4885CACNA1G 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.